ArticleClinical ophthalmology (Auckland, N.Z.)2025
Multicenter Retrospective Analysis of Intraoperative Aberrometer Measurements and Associated Visual Outcomes with a Monofocal Aspheric Intraocular Lens.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the real-world performance of Clareon Patients and Methods: This retrospective, postmarket analysis included anonymized data from a multicenter study conducted in the US. Data were collected from patients implanted with Clareon ultraviolet-absorbing (UVA) monofocal or monofocal Toric IOL(s), utilizing the WaveTec ORA System and had available corrected distance visual acuity (CDVA) data at 28 days to 3 years postoperative. The primary endpoint was the percentage of eyes achieving monocular CDVA of 20/40 at ≥ 1 month postoperative. Secondary and exploratory endpoints included monocular uncorrected distance visual acuity (UDVA), residual refractive cylinder, stratified visual acuity (VA) thresholds, manifest refraction spherical equivalent (MRSE), and prediction error comparisons between ORA and preoperative biometry. Results: Based on 1404 eyes, 98.4% achieved CDVA of 20/40 or better (mean logMAR 0.04 non-Toric, 0.03 Toric). Among emmetropia targeted eyes, 93.9% achieved UDVA of 20/40 or better. The mean residual refractive cylinder for Toric models was 0.40 diopters (D). The mean (standard deviation) MRSE was -0.15 (0.45) D. The mean prediction error for emmetropia targeted eyes was -0.10 (0.49) D. Additionally, 78.7% had prediction error differences within ± 0.25 D between ORA and preoperative biometry. In 40.8% of cases, the implanted IOLs match the preoperative selection with no clinically significant VA differences between match and unmatch eyes. Conclusion: Most patients implanted with the Clareon UVA IOLs, using WaveTec ORA IA achieved CDVA of 20/40 or better at ≥ 1 month postoperatively, with minimal residual refractive error and enhanced target accuracy, indicating ORA may support optimize IOL power calculation and axis positioning to improve refractive outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.